Navigating competitive arenas in rare disease
Treatment choice is beneficial for people living with rare diseases (RDs) and competition can drive important economic advantages for payers.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Kira Gordon is a Principal in the Life Sciences Practice at CRA specializing in strategy consulting. She has consulted on projects across number of therapeutic areas and healthcare markets.
Her project work focuses primarily on pricing & market access strategy and opportunity assessment/diligence support. Ms. Gordon has experience with both drugs and devices across a broad range of therapy areas, with a particular emphasis on medical-surgical devices, hospital drugs, metabolic syndrome, and outpatient specialty therapeutics in categories including oncology, neurology-psychology, autoimmune, and rare disease.